ENDPOINTS NEWS3h
At least six drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions
Half of drugmakers join Medicare price talks, including Amgen, Boehringer Ingelheim, AstraZeneca, Astellas, Bristol Myers ...
ENDPOINTS NEWS3h
Bi­par­ti­san 'pill penal­ty' fix and oth­er bills vie for in­clu­sion in rec­on­cil­i­a­tion pack­age
Industry groups are looking to push government drug price negotiation and PBM reforms into a massive Republican domestic ...
ENDPOINTS NEWS5h
CHMP rec­om­mends Re­gen­eron, No­var­tis drugs that still await FDA ap­proval
CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...
ENDPOINTS NEWS7h
Prax­is says its es­sen­tial tremor drug failed a Phase 3 read­out but plans to com­plete study
Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price down ...
ENDPOINTS NEWS6h
In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el
Infectious disease professionals, bracing for an overhaul of the CDC's vaccine advisory group, are in discussions to stand up ...
ENDPOINTS NEWS10h
Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen
BridgeBio Oncology Therapeutics to go public via merger with Helix Acquisition Corp. II SPAC, led by Bihua Chen's Cormorant, ...
ENDPOINTS NEWS11h
Trump’s science crackdown hits rare disease medicine: ‘We need to sit down with Elon Musk’
Jill Wood had pinned her hopes on a little-known federal program to fund her son’s gene therapy. The initiative, which awards ...
ENDPOINTS NEWS11h
Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves
William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...
ENDPOINTS NEWS1d
HHS’ vac­cine in­jury pan­el in lim­bo af­ter month­long meet­ing de­lay
More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal ...
ENDPOINTS NEWS1d
Phar­ma-backed Mis­sion Ther­a­peu­tics stops pre­clin­i­cal op­er­a­tions, fo­cus­es on two clin­i­cal as­sets
Clinical-stage biotech Mission Therapeutics is closing its preclinical laboratory operations in Cambridge, UK, a spokesperson ...
ENDPOINTS NEWS1d
Kally­ope qui­et­ly re­ports Phase 2 obe­si­ty da­ta, be­gins mid-stage mi­graine tri­al
Kallyope's Phase 2 obesity trial shows K-757 and K-833 combo achieved 2.9% weight loss vs 0.2% for placebo. Results fall ...
ENDPOINTS NEWS1d
Drug pol­i­cy vet­er­an at CMS to de­part on Fri­day
John Coster, CMS' senior technical advisor for the Medicare drug rebate and negotiation group, told Endpoints News that he's ...